World Journal of Gastroenterology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 3

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1017)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

HTML

369

Figures (1-2)

Tables (1-3)

Sum=523

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

186

Sum=270

Publishing Process of This Article

Item

Count

Browse

Download

121

Sum=172

Jan 21, 2026 (publication date) through Mar 28, 2026

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Ascari S, Chen R, De Sinno A, Stefanini B, Cescon M, Serenari M, Mosconi C, Tovoli F. Post-immunotherapy second-line strategies for hepatocellular carcinoma: State of the art and ongoing trials. World J Gastroenterol 2026; 32(3): 111528 [PMID: 41640611 DOI: 10.3748/wjg.v32.i3.111528]
URL:	https://www.wjgnet.com/1007-9327/full/v32/i3/111528.htm

Number	Citing Articles
1	Daichi Takizawa, Hirotaka Arai, Mitsuhiko Shibasaki, Yuki Tamura, Satoru Kakizaki, Takeshi Hatanaka, Atsushi Naganuma, Takashi Ueno, Toru Fukuchi, Masashi Namikawa, Satoshi Takakusagi, Shuichi Saito, Takayoshi Suga, Hiroki Tojima, Yuichi Yamazaki, Toshio Uraoka. Efficacy of Lenvatinib as Second-Line Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma. Current Oncology 2026; 33(3): 159 doi: 10.3390/curroncol33030159

Number

Citing Articles

Daichi Takizawa, Hirotaka Arai, Mitsuhiko Shibasaki, Yuki Tamura, Satoru Kakizaki, Takeshi Hatanaka, Atsushi Naganuma, Takashi Ueno, Toru Fukuchi, Masashi Namikawa, Satoshi Takakusagi, Shuichi Saito, Takayoshi Suga, Hiroki Tojima, Yuichi Yamazaki, Toshio Uraoka. Efficacy of Lenvatinib as Second-Line Therapy After Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma. Current Oncology 2026; 33(3): 159 doi: 10.3390/curroncol33030159